Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.44 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5284581 | 0.95 | GSK3B (0.47) | HTR2BGLAGSK3BMEP1AMEP1B | |
| SCHEMBL2058688 | 0.89 | GLA (0.47) | HTR2BGLAGSK3BMEP1AMEP1B | |
| SCHEMBL28865565 | 0.88 | HTR2B (0.50) | HTR2BGLAMEP1AMEP1BCYP19A1 | |
| SCHEMBL28248372 | 0.88 | HTR2B (0.54) | HTR2BGLAMEP1AMEP1BCYP19A1 | |
| SCHEMBL24358855 | 0.86 | HTR2B (0.49) | HTR2BGLAMEP1AMEP1BCYP19A1 | |
| SCHEMBL29732423 | 0.86 | HTR2B (0.49) | HTR2BGLAMEP1AMEP1BCYP19A1 | |
| SCHEMBL2154019 | 0.84 | GLA (0.53) | HTR2BGLAGSK3BMEP1AMEP1B | |
| SCHEMBL6962952 | 0.83 | DRD2 (0.49) | HTR2BGLAKCNJ1KCNH2FFAR1 | |
| SCHEMBL5545471 | 0.81 | HTR2B (0.46) | HTR2BGLAMEP1AMEP1BCYP19A1 | |
| SCHEMBL6951637 | 0.81 | FAAH (0.50) | HTR2BGLAKCNJ1KCNH2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-2226323-A1 | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives | Almirall, S.A. (ES) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226323-A1 | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives | Almirall, S.A. (ES) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010097172-A1 | NEW TETRAHYDROPYRAZOLO[3,4-C]ISOQUINOLIN-5-AMINE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-09-02 | — | — | WO | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-0976722-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | disclosed |
| EP-0658538-B1 | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA INC (US) | 1997-10-29 | — | — | EP | disclosed |
| EP-0329464-B1 | System for the closed-loop administration of an exercise simulating agent | GENSIA INC (US) | 1995-11-02 | — | — | EP | disclosed |
| US-5460605-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA, INC. (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0658538-A1 | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA, INC. (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5395970-A | 1-(3,4-dihydroxyphenyl)-2-(4-(4-hydroxyphenyl)butaylamino)ethanol | GENSIA PHARMACEUTICALS, INC. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5286252-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA PHARMACEUTICALS, INC. (US) | 1994-02-15 | — | — | US | disclosed |
| US-5234404-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA PHARMACEUTICALS, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5108363-A | DIAGNOSIS, EVALUATION AND TREATMENT OF CORONARY ARTERY DISEASE BY EXERCISE SIMULATION USING CLOSED LOOP DRUG DELIVERY OF AN EXERCISE SIMULATING AGENT BETA AGONIST | GENSIA PHARMACEUTICALS, INC. (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0329464-A2 | System for the closed-loop administration of an exercise simulating agent | GENSIA, INC. (US) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029980-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | HTR2B 2741/4885GLA 2928/4885GSK3B 3527/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | HTR2B 429/4885GLA 2688/4885GSK3B 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.